Latest Breaking News On - Annual congress - Page 1 : comparemela.com

foundry-planet com - B2B Portal: 7 reasons to come to Metal China 2024

7 reasons to come to Metal China 2024

Europe diecasting technology dayConvention center shanghaiChina foundry associationNational exhibitionDiecasting chinaConvention centerMetal chinaAnnual congressChina foundryChain synergy

Investigational Antipsychotic Demonstrates Efficacy Without Blocking Dopamine Receptor

Investigational agent KarXT is a first-in-class muscarinic receptor agonist demonstrating antipsychotic efficacy and safety in short- and long-term clinical trials.

United statesRaymond ortonRonald marcusInvega trinzaSamatha yohnBristol myers squibbCenexel hassman research instituteSchizophrenia international research societyKaruna therapeuticsPsychiatric timesNew drug applicationBristol myersAnnual congressSchizophrenia international research

New Post-Hoc Analysis of Pooled Phase 3 Data Shows That Inpefa (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection Fraction

Analysis adds to the body of evidence differentiating INPEFA as a dual oral inhibitor of SGLT2 and SGLT1

United statesCraig granowitzLexicon pharmaceuticals incAmerican heart associationAmerican college of cardiologyAnnual congressHeart failure associationEuropean societyAmerican college

Sanofi: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3

ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3 Sarclisa, in combination

France generalUnited statesTarik elgoutniThomas kudsk larsenFelix lauscherKeita browneEvan berlandPeterc adamsonSandrine guendoulTimothy gilbertThierry faconNathalie phamFrench academy of medicineDrug administrationAmerican society of clinical oncologyLille university hospital

Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3

Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3
finanzen.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanzen.at Daily Mail and Mail on Sunday newspapers.

France generalUnited statesEvan berlandTarik elgoutniPeterc adamsonSandrine guendoulTimothy gilbertThomas kudsk larsenNathalie phamFelix lauscherThierry faconKeita browneEuropean unionWorld health organizationLille university hospitalDrug administration